Hold Rating for United Therapeutics Amid Mixed Tyvaso Performance and Competitive Challenges

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on United Therapeutics, retaining the price target of $328.00.

Terence Flynn’s rating is based on a balanced assessment of United Therapeutics’ current market position and future prospects. The company’s Tyvaso product has shown mixed sales performance, with a slight increase in DPI sales but a decrease in nebulized sales. Despite this, Tyvaso’s market penetration in interstitial lung disease is growing, which is a positive sign.
However, the competitive landscape presents challenges. The recent FDA approval of a rival product, Yutrepia, introduces potential competition, although United Therapeutics believes its product remains well-positioned. Additionally, while there are promising pipeline developments, such as the upcoming data from the Tyvaso TETON-2 and TETON-1 trials, the full impact of these developments will not be realized until several years down the line. This combination of factors contributes to the Hold rating, reflecting a cautious yet optimistic outlook.

In another report released today, Wells Fargo also assigned a Hold rating to the stock with a $295.00 price target.

UTHR’s price has also changed moderately for the past six months – from $352.300 to $281.950, which is a -19.97% drop .